

Ascletois gets pharmaceutical trade license and GSP certificate

02 December 2019 | News | By Sonali Wankhade

With a well-established GSP quality management system, modern logistics facilities and equipment, AscletoisXinNuo has ensured the quality control of products over its drug distribution process



Ascletois Pharma, an innovative R&D driven, commercial-stage biotechnology company addressing unmet medical needs in therapeutic areas including anti-viral, cancer and fatty liver diseases, announces today that Ascletois XinNuo Medicine (HangZhou) Co.,Ltd. (hereinafter referred to as Ascletois XinNuo), a wholly-owned subsidiary of Ascletois, has recently obtained the Pharmaceutical Trade License and GSP Certificate issued by ZheJiang Medical Products Administration.

The business scope of Ascletois XinNuo composes of drug distribution, and import & export agency. It mainly covers major kinds of innovative drugs manufactured directly by Ascletois and via its business partners. With a well-established GSP quality management system, modern logistics facilities and equipment, Ascletois XinNuo has ensured the quality control of products over its drug distribution process.

“Ascletois has developed into an integrated platform from drug discovery and development to manufacturing and commercialization,” said Jinzi J. Wu, PhD, Founder, Chairman and CEO of Ascletois, “Obtaining Pharmaceutical Trade License and GSP Certificate marks another milestone in Ascletois’ commercialization layout. This has enabled Ascletois to position as the best partner within the innovative pharmaceutical industry by achieving an open and full cooperation throughout the entire industry chain.”

In the future, Ascletois will import potentially innovative medical products worldwide through Ascletois XinNuo, in order to further strengthen its product pipeline of innovative drugs. At the same time, Ascletois XinNuo will develop its international cooperation, to benefit patients in countries and regions under the Belt and Road Initiative with its global first-in-class innovative drugs.